Growing community of inventors

Portland, OR, United States of America

Jeffrey Tyner

Average Co-Inventor Count = 4.76

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 4

Jeffrey TynerLawrence D Mayer (2 patents)Jeffrey TynerPaul Tardi (2 patents)Jeffrey TynerStephen Kurtz (2 patents)Jeffrey TynerMax Gordon (2 patents)Jeffrey TynerBrian Jay Druker (1 patent)Jeffrey TynerShannon K McWeeney (1 patent)Jeffrey TynerShannon Mcweeny (1 patent)Jeffrey TynerCristina Tognon (1 patent)Jeffrey TynerDaniel Bottomly (1 patent)Jeffrey TynerBeth Wilmot (1 patent)Jeffrey TynerElie Traer (1 patent)Jeffrey TynerNicola Long (1 patent)Jeffrey TynerSamantha Savage Stevens (1 patent)Jeffrey TynerTamilla Nechiporuk (1 patent)Jeffrey TynerAnna Reister Schultz (1 patent)Jeffrey TynerJeffrey Tyner (4 patents)Lawrence D MayerLawrence D Mayer (31 patents)Paul TardiPaul Tardi (16 patents)Stephen KurtzStephen Kurtz (2 patents)Max GordonMax Gordon (2 patents)Brian Jay DrukerBrian Jay Druker (9 patents)Shannon K McWeeneyShannon K McWeeney (2 patents)Shannon McweenyShannon Mcweeny (1 patent)Cristina TognonCristina Tognon (1 patent)Daniel BottomlyDaniel Bottomly (1 patent)Beth WilmotBeth Wilmot (1 patent)Elie TraerElie Traer (1 patent)Nicola LongNicola Long (1 patent)Samantha Savage StevensSamantha Savage Stevens (1 patent)Tamilla NechiporukTamilla Nechiporuk (1 patent)Anna Reister SchultzAnna Reister Schultz (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Oregon Health & Science University (4 from 505 patents)

2. Celator Pharmaceuticals, Inc. (2 from 25 patents)


4 patents:

1. 12472175 - Methods of treating venetoclax-resistant acute myeloid leukemia

2. 12268690 - Treatments for mutations in acute myeloid leukemia

3. 11746386 - Assays and methods for selecting a treatment regimen for a subject with leukemia

4. 10927418 - Assays and methods for selecting a treatment regimen for a subject with leukemia

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/26/2025
Loading…